Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

526 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alpha-glucosidase inhibitor, acarbose, improves glycamic control and reduces body weight in type 2 diabetes: Findings on indian patients from the pooled data analysis.
Kalra S, Sahay RK, Schnell O, Sheu WH, Grzeszczak W, Watada H, Soegondo S, Yamamoto N, Weng J, Rathod R. Kalra S, et al. Among authors: watada h. Indian J Endocrinol Metab. 2013 Oct;17(Suppl 1):S307-9. doi: 10.4103/2230-8210.119634. Indian J Endocrinol Metab. 2013. PMID: 24251196 Free PMC article.
Acarbose reduces body weight irrespective of glycemic control in patients with diabetes: results of a worldwide, non-interventional, observational study data pool.
Schnell O, Weng J, Sheu WH, Watada H, Kalra S, Soegondo S, Yamamoto N, Rathod R, Zhang C, Grzeszczak W. Schnell O, et al. Among authors: watada h. J Diabetes Complications. 2016 May-Jun;30(4):628-37. doi: 10.1016/j.jdiacomp.2016.01.023. Epub 2016 Feb 2. J Diabetes Complications. 2016. PMID: 26935335
Effects of linagliptin vs. voglibose on daily glucose excursions during continuous glucose monitoring of Japanese type 2 diabetes patients (L-CGM): A randomized, open-label, two-arm, parallel comparative trial.
Satoh H, Ohira T, Moriya C, Inoue I, Kuribayashi S, Seino H, Hirai H, Hiyoshi T, Watada H; L-CGM Study Group. Satoh H, et al. Among authors: watada h. Diabetes Metab. 2017 Dec;43(6):550-553. doi: 10.1016/j.diabet.2017.07.010. Epub 2017 Sep 22. Diabetes Metab. 2017. PMID: 28947255 Clinical Trial. No abstract available.
Effect of real-life insulin pump with predictive low-glucose management use for 3 months: Analysis of the patients treated in a Japanese center.
Tsunemi A, Sato J, Kurita M, Wakabayashi Y, Waseda N, Koshibu M, Shinohara M, Ozaki A, Nakamura H, Hirano N, Ikeda F, Satoh H, Watada H. Tsunemi A, et al. Among authors: watada h. J Diabetes Investig. 2020 Nov;11(6):1564-1569. doi: 10.1111/jdi.13288. Epub 2020 Jun 10. J Diabetes Investig. 2020. PMID: 32374513 Free PMC article.
Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.
Terauchi Y, Yabe D, Kaneto H, Amano A, Baxter M, Watanabe D, Watada H, Inagaki N. Terauchi Y, et al. Among authors: watada h. Diabetes Obes Metab. 2020 Sep;22 Suppl 4:35-47. doi: 10.1111/dom.14139. Diabetes Obes Metab. 2020. PMID: 33404200 Clinical Trial.
526 results